Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials | Zendy

Yi Wang | Zendy; Lingyan Xu | Zendy; Xianghu Meng | Zendy; Zhiqiang Qin | Zendy; Yamin Wang | Zendy; Chen Chen | Zendy; Yichun Wang | Zendy; Xiang Zhou | Zendy; Qijie Zhang | Zendy; Jiadong Xia | Zendy; Ninghong Song | Zendy

Open Access

Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials

Author(s) -

Yi Wang,

Lingyan Xu,

Xianghu Meng,

Zhiqiang Qin,

Yamin Wang,

Chen Chen,

Yichun Wang,

Xiang Zhou,

Qijie Zhang,

Jiadong Xia,

Ninghong Song

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000493951

Subject(s) - oncology , gemcitabine , medicine , hazard ratio , chemotherapy , randomized controlled trial , progression free survival , confidence interval

Urothelial cancer (UC) as a chemotherapy-sensitive tumor, has achieved remarkable progresses in therapeutic paradigm, particularly in the advanced/metastatic stages. However, both clinicians and patients are confused when it comes to choosing the optimal chemotherapy. Hence, this article was aimed to conduct a comprehensive comparison of different chemotherapy regimens for advanced or metastatic UC in terms of survival benefits or adverse events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research